Darunavir: A Critical Review of Its Properties, Use and Drug Interactions

Página do item simplificado
dc.contributor.authorRuela Correa, Josilene Chaves [UNESP]
dc.contributor.authorD'Arcy, Deirdre M.
dc.contributor.authordos Reis Serra, Cristina Helena
dc.contributor.authorSalgado, Hérida Regina Nunes [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionTrinity Coll Dublin
dc.date.accessioned2014-05-20T13:24:55Z
dc.date.available2014-05-20T13:24:55Z
dc.date.issued2012-01-01
dc.description.abstractDarunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wildtype HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment. Copyright (C) 2012 S. Karger AG, Baselen
dc.description.affiliationUniv Estadual Paulista, Sch Pharmaceut Sci, Drugs & Med Qual Control Lab, BR-14801902 Araraquara, Brazil
dc.description.affiliationUniv São Paulo, Sch Pharmaceut Sci, São Paulo, Brazil
dc.description.affiliationTrinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland
dc.description.affiliationUnespUniv Estadual Paulista, Sch Pharmaceut Sci, Drugs & Med Qual Control Lab, BR-14801902 Araraquara, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação para o Desenvolvimento da UNESP (FUNDUNESP)
dc.description.sponsorshipPADC-UNESP
dc.format.extent102-109
dc.identifierhttp://dx.doi.org/10.1159/000339862
dc.identifier.citationPharmacology. Basel: Karger, v. 90, n. 1-2, p. 102-109, 2012.
dc.identifier.doi10.1159/000339862
dc.identifier.issn0031-7012
dc.identifier.urihttp://hdl.handle.net/11449/7862
dc.identifier.wosWOS:000307156100011
dc.language.isoeng
dc.publisherKarger
dc.relation.ispartofPharmacology
dc.relation.ispartofjcr1.538
dc.relation.ispartofsjr0,502
dc.rights.accessRightsAcesso aberto
dc.sourceWeb of Science
dc.subjectDarunaviren
dc.subjectHuman immunodeficiency virusen
dc.subjectAcquired immune deficiency syndromeen
dc.subjectClinical pharmacokineticsen
dc.subjectDrug interactionsen
dc.subjectBiopharmaceutics classification systemen
dc.titleDarunavir: A Critical Review of Its Properties, Use and Drug Interactionsen
dc.typeArtigo
dcterms.licensehttp://www.karger.com/Journal/Guidelines/238704#15
dcterms.rightsHolderKarger
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos

Licença do Pacote
Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Araraquara - FCF - Faculdade de Ciências Farmacêuticas